Home > Insider Trading > Filing (0001209191-19-060295)

Filing Details

Accession Number:: 0001209191-19-060295
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-12-12 19:54:41
Reporting Period:: 2019-12-10

Accepted Time:: 2019-12-12 19:54:41
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1595893	Turning Point Therapeutics Inc.	TPTX	Pharmaceutical Preparations (2834)	463826166

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1772259	Jean Jingrong Cui	C/O Turning Point Therapeutics, Inc. 10628 Science Center Drive, Ste. 200 San Diego CA 92121	Chief Scientific Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-12-10	2,700	$53.79	1,058,019	No	4	S	Indirect	By spouse
Common Stock	Disposition	2019-12-10	8,700	$54.81	1,049,319	No	4	S	Indirect	By spouse
Common Stock	Disposition	2019-12-10	100	$55.51	1,049,219	No	4	S	Indirect	By spouse
Common Stock	Disposition	2019-12-11	8,928	$52.72	1,040,291	No	4	S	Indirect	By spouse
Common Stock	Disposition	2019-12-11	2,452	$53.67	1,037,839	No	4	S	Indirect	By spouse
Common Stock	Disposition	2019-12-11	120	$54.20	1,037,719	No	4	S	Indirect	By spouse
Common Stock	Disposition	2019-12-12	500	$53.18	1,037,219	No	4	S	Indirect	By spouse
Common Stock	Disposition	2019-12-12	10,900	$54.15	1,026,319	No	4	S	Indirect	By spouse
Common Stock	Disposition	2019-12-12	100	$54.66	1,026,219	No	4	S	Indirect	By spouse

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By spouse
No	4	S	Indirect	By spouse
No	4	S	Indirect	By spouse
No	4	S	Indirect	By spouse
No	4	S	Indirect	By spouse
No	4	S	Indirect	By spouse
No	4	S	Indirect	By spouse
No	4	S	Indirect	By spouse
No	4	S	Indirect	By spouse

Footnotes

Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li.
The weighted average sale price for the transaction reported was $53.79, and the range of prices were between $53.34 and $54.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $54.81, and the range of prices were between $54.36 and $55.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $52.72, and the range of prices were between $52.15 and $53.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $53.67, and the range of prices were between $53.19 and $54.18. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $53.18, and the range of prices were between $52.63 and $53.58. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $54.15, and the range of prices were between $53.64 and $54.6050. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.